title: Cellular and molecular chaperone fusion vaccines: targeting resistant cancer cell populations.
abstract: Molecular chaperone-based vaccines offer a number of advantages for cancer treatment. We have discussed the deployment of a vaccine prepared by gentle isolation of Hsp70 from tumour dendritic cell fusions (Hsp70 fusion vaccine). The vaccine was highly effective in triggering specific T cell immunity and in the treatment of tumour-bearing mice and the preparation was shown to retain an increased amount of tumour antigens compared to other chaperone-based isolates. This approach has the further advantage that tumour sub-populations could be used to prepare the Hsp70 fusion vaccine. Cellular fusion vaccines were made to specifically target drug-resistant cancer cells and tumour cell populations enriched in ovarian cancer stem cells (CSC). Such vaccines showed enhanced capacity to trigger T cell immunity to these resistant ovarian carcinoma populations. We have discussed the potential of using the cellular and Hsp70 fusion vaccine approaches in therapy of treatment-resistant cancer cells and its deployment in combination with ionising radiation or hyperthermia to enhance the effectiveness of both forms of therapy.
authors.affiliation: Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. scalderw@bidmc.harvard.edu
authors.forename: Stuart K
authors.initials: SK
authors.lastname: Calderwood
authors.forename: Jianlin
authors.initials: J
authors.lastname: Gong
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Stevenson
authors.forename: Ayesha
authors.initials: A
authors.lastname: Murshid
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014411:Neoplastic Stem Cells
chemical_list: D019496:Cancer Vaccines; D018840:HSP70 Heat-Shock Proteins